management of this severe acute and rare Diagnosis No By which specialty condition. must be verified Exclusion Autoimmune haemolytic anaemia (AIHA) Exclusion criteria have been defined to Criteria support evidence based prescribing practice. Alloimmune delayed haemolytic transfusion reaction with a positive AIHA is excluded because it is a standalone direct agglutination test where haemolysis of only transfused red condition in the Emerging role category (the cells is suspected. system will link users to the correct condition). There is insufficient evidence of benefit for the use of Ig therapy in delayed allo-immune reaction. There have been only six cases reported in the literature across two papers with the evidence being very weak with four of the six cases being auto-antibodies. Qualifying Severe haemolytic transfusion reactions where there is Qualifying criteria have now been developed Criteria suspected haemolysis of both donor and recipient red cells to align with the literature. The supporting as evidenced by a fall in haemoglobin below pre-transfusion evidence items will confirm that the drop in levels haemoglobin is related to the transfusion, AND compare the significance of drop in Ig therapy is given in conjunction with high dose haemoglobin compared with the transfusion corticosteroids volume, and that ensure intravenous steroids are being given in combination with Ig therapy. Review Review is not mandated for this condition however the following Review is not mandated for this condition Criteria criteria may be useful in assessing the effectiveness of therapy. because treatment is by one-off dose. Clinical effectiveness of Ig therapy can be demonstrated by:
management of this severe acute and rare condition. Diagnosis must be verified No By which specialty Exclusion Criteria Autoimmune haemolytic anaemia (AIHA) Alloimmune delayed haemolytic transfusion reaction with a positive direct agglutination test where haemolysis of only transfused red cells is suspected. Exclusion criteria have been defined to support evidence based prescribing practice. AIHA is excluded because it is a standalone condition in the Emerging role category (the system will link users to the correct condition). There is insufficient evidence of benefit for the use of Ig therapy in delayed allo-immune reaction. There have been only six cases reported in the literature across two papers with the evidence being very weak with four of the six cases being auto-antibodies. Qualifying Criteria Severe haemolytic transfusion reactions where there is suspected haemolysis of both donor and recipient red cells as evidenced by a fall in haemoglobin below pre-transfusion levels AND Ig therapy is given in conjunction with high dose corticosteroids Qualifying criteria have now been developed to align with the literature. The supporting evidence items will confirm that the drop in haemoglobin is related to the transfusion, compare the significance of drop in haemoglobin compared with the transfusion volume, and that ensure intravenous steroids are being given in combination with Ig therapy. Review Criteria Review is not mandated for this condition however the following criteria may be useful in assessing the effectiveness of therapy. Clinical effectiveness of Ig therapy can be demonstrated by: Review is not mandated for this condition because treatment is by one-off dose.
Haemolytic-transfusion-reaction-not-associated-with-red-cell-antibodies2017.docx